Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328161 | 0.82 | KDM4E (0.31) | KDM4EMAPTALDH1A1GAAHTT | |
| SCHEMBL13360489 | 0.73 | KDM4E (0.33) | KDM4EMAPTALDH1A1GAAHTT | |
| SCHEMBL14221400 | 0.71 | KDM4E (0.30) | KDM4EMAPT | |
| SCHEMBL18876216 | 0.70 | KDM4E (0.32) | KDM4EMAPTALDH1A1GAAHTT | |
| SCHEMBL18876287 | 0.70 | KDM4E (0.32) | KDM4EMAPTALDH1A1GAAHTT | |
| SCHEMBL1121529 | 0.70 | KDM4E (0.32) | KDM4EMAPTALDH1A1GAAHTT | |
| SCHEMBL18876124 | 0.69 | GPR35 (0.34) | — | |
| SCHEMBL9414147 | 0.69 | KDM4E (0.34) | KDM4EMAPTALDH1A1GAAHTT | |
| SCHEMBL24595786 | 0.67 | KDM4E (0.30) | KDM4EMAPT | |
| SCHEMBL12425595 | 0.67 | GPR3 (0.46) | KDM4EMAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572784-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | KDM4E 774/4885MAPT 676/4885ALDH1A1 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.